NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

INAB

NASDAQ:INABNASDAQ
1 announcements
Credibility Score65%
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
OverhypedModerate hypeunclear

Repeat-dose gamma-delta T cell therapy shows doubled survival in glioblastoma versus standard care.

13 minutes ago
▼